NCT07631871尚未招募2 期
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
Haihua Yuan0 个研究点目标入组 10 人开始时间: 2026年6月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
- 主要终点
- Objective Response Rate, ORR
研究概览
简要总结
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2 positive advanced solid tumors? Participants will receive Zanidatamab intravenously on Day 1 of each 2-week treatment cycle. The dosage is 20 mg/kg per cycle.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged ≥ 18 years old.
- •Subjects with locally advanced, unresectable or metastatic solid tumors who have progressed after ≥1 prior systemic therapy for advanced/metastatic disease, or have no available optimal alternative treatments. Qualified tumor types include but are not limited to endometrial carcinoma, urothelial carcinoma, pancreatic cancer, colorectal carcinoma (CRC), head and neck adenocarcinoma (salivary gland adenocarcinoma, lacrimal gland adenocarcinoma, adenocarcinoma of unknown primary of the neck), cervical cancer, ovarian cancer and adenocarcinoma of unknown primary. Biliary tract malignancy, lung cancer and breast cancer are excluded. For CRC patients: documented RAS status (wild-type or mutant) and wild-type BRAF; prior treatment regimen should contain fluoropyrimidine, oxaliplatin and irinotecan unless contraindicated; anti-VEGF therapy when clinically indicated; anti-PD-L1 therapy for MSI-H/dMMR tumors if clinically indicated.
- •ECOG Performance Status 0, 1 or
- •Confirmed HER2 positivity defined as IHC 3+, or IHC 2+ with positive FISH amplification (per GC criteria).
- •Willing and capable of providing adequate tumor specimens for central pathological re-assessment of HER2 status at institutional pathology department. Patients previously treated with HER2-ADC must provide FFPE tumor samples collected after last HER2-ADC administration. Specimens with insufficient tumor cellularity and fine-needle aspiration samples are not acceptable for HER2 testing.
- •At least one measurable lesion at baseline per RECIST 1.1 criteria.
- •Adequate bone marrow and organ function confirmed within 14 days prior to enrollment: Hemoglobin ≥ 9 g/dL; Platelet count ≥ 75,000/mm³; Absolute neutrophil count (ANC) ≥ 1000/mm³; Serum albumin ≥ 2.5 g/dL; PT, aPTT and INR ≤ 1.5 × ULN; AST/ALT ≤ 3 × ULN; ≤5 × ULN for subjects with liver metastasis; Total bilirubin ≤1.5 × ULN (no liver metastasis); ≤3 × ULN (baseline Gilbert syndrome or liver metastasis); Creatinine clearance ≥30 mL/min (calculated by Cockcroft-Gault formula)
- •LVEF ≥50% evaluated via echocardiogram (ECHO) or MUGA scan within 28 days before enrollment.
排除标准
- •Subjects with any of the following conditions are ineligible:
- •Documented spinal cord compression, leptomeningeal disease or clinically active central nervous system (CNS) metastasis.
- •Active primary immunodeficiency, confirmed HIV infection, active HBV or HCV infection.
- •History of non-infectious interstitial lung disease (ILD)/non-infectious pneumonia requiring steroid therapy, ongoing active ILD/non-infectious pneumonia, or suspected ILD/non-infectious pneumonia that cannot be ruled out by screening imaging.
- •History of myocardial infarction, symptomatic congestive heart failure (CHF, NYHA Class II-IV), unstable angina, or any cardiovascular event (including stroke) within 6 months prior to enrollment.
- •Pulmonary exclusion items: (a) Clinically significant underlying pulmonary disorders, including but not limited to pulmonary embolism within 3 months before screening, severe asthma, severe COPD, restrictive lung disease, recurrent pleural effusion; (b) Confirmed autoimmune, connective tissue or inflammatory diseases (rheumatoid arthritis, Sjögren's syndrome, sarcoidosis etc.), or suspected pulmonary involvement at screening; full disease details shall be recorded in eCRF for enrolled subjects; (c) Previous total pneumonectomy.
- •Confirmed presence of HER2 gene mutation.
研究组 & 干预措施
Zanidatamab
Experimental
Zanidatamab is administered intravenously at a dose of 20 mg/kg on Day 1 of every 2-week treatment cycle.
干预措施: Zanidatamab (Drug)
结局指标
主要结局
Objective Response Rate, ORR
时间窗: From the date of first study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 24months.
The Objective Response Rate (ORR) is defined as the percentage of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
次要结局
- Duration of Response, DOR(From the date of first documented response (complete response [CR] or partial response [PR]) to the time of disease progression or death from any cause, whichever occurs first, assessed up to 24months.)
- Disease Control Rate, DCR(From the date of first study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 24 months.)
- Best Overall Response, BOR(Through study completion, average follow-up of 2 years.)
- Progression-Free Survival, PFS(Through study completion, an average of 2 years.)
- Overall Survival, OS(Through study completion, an average of 2 years.)
- Adverse Events, AEs(From first study drug administration through 40 days after the last dose; overall average follow-up duration is 2 years.)
研究者
Haihua Yuan
Principal Investigator, Clinical Professor, Chief Physician, Department of Oncology, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
相似试验
尚未招募
不适用
Zanidatamab Combined With Chemotherapy as Neoadjuvant Therapy for HER2-high Expression G/GEJCGastric/Gastroesophageal Junction AdenocarcinomaNCT07273981Xijing Hospital30
尚未招募
1 期
Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal CancerGastroesophageal CancerNCT07477444Universitaire Ziekenhuizen KU Leuven29
Unknown
不适用
一项评价 Zanidatamab 联合标准疗法对比仅接受标准疗法治疗晚期 HER2 阳性胆道癌的有效性和安全性的开放性、随机试验局部晚期、不可切除或转移性 HER2 阳性胆道癌ChiCTR2500098089Jazz Pharmaceuticals Ireland Limited（全球）/ 百济神州（苏州）生物科技有限公司（仅限中国）
招募中
3 期
一项评价 Zanidatamab 治疗晚期 HER2 阳性胆道癌的开放性、随机试验晚期 HER2 阳性胆道癌CTR20251721百济神州（苏州）生物科技有限公司
招募中
不适用
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor PatientsPan-tumor(NSCLC, GYN Cancers, BTC and UC)NCT07404202AstraZeneca2,100